Bellerophon Therapeutics
formerly BellerophonIPO- Headquarters
- Warren, New Jersey
- Employees
- 11–50
- Business Model
- B2B
- Website
- bellerophon.com
About
Bellerophon Therapeutics is a clinical-stage biopharmaceutical company developing INOpulse, a pulsed, inhaled nitric oxide delivery system for pulmonary arterial hypertension and related cardiopulmonary conditions. The company (NASDAQ/OTC: BLPH) has run multiple Phase 2b/3 clinical trials evaluating INOpulse across different patient populations, including pulmonary hypertension associated with fibrotic interstitial lung disease.
Summary
Bellerophon Therapeutics is a Biotech company based in Warren, United States. Investors include Cowen and Company and SVB Leerink.
Funding History
Feb 2015
Investors
Similar Companies
China's leading blood products manufacturer
One of the world's largest contract research organizations (CROs), providing end-to-end clinical ...
Global contract development and manufacturing organization (CDMO) focused exclusively on sterile ...
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/bellerophon-therapeutics"><img src="https://indexed.vc/api/badge/company/bellerophon-therapeutics" alt="Bellerophon Therapeutics on Indexed.vc" width="260" height="76" /></a>